Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 5,000
- Avg volume
- —
- Day's range
- $0.16 – $0.16
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc....
Show more
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 514 796 2640
- Website
- https://rizeoncology.com
- Address
- 301 – 1665 Ellis Street, Kelowna, Canada
Latest news
No headlines yet.
